Lineage Cell Therapeutics: Q1 Earnings Insights
Lineage Cell Therapeutics: Q1 Earnings Insights
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.
Revenue was down $2.85 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.01 which was followed by a 2.05% drop in the share price the next day.
Here's a look at Lineage Cell Therapeutics's past performance:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | -0.04 | -0.03 | -0.04 | -0.03 |
EPS Actual | -0.03 | -0.04 | -0.04 | -0.04 |
Revenue Estimate | 2.57M | 3.90M | 3.68M | 7.32M |
Revenue Actual | 1.90M | 3.00M | 4.55M | 5.24M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:01 PM.
譜系細胞療法 (AMEX: LCTX) 於 2023 年 5 月 11 日星期四下午 4:01 公佈了第一季度財報。
Here's what investors need to know about the announcement.
以下是投資者需要了解的有關該公告的信息。
Earnings
收益
Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.
Lineage Cell Therapeutics的收益比預期高出25.0%,報告的每股收益爲-0.03美元,而預期爲-0.04美元。
Revenue was down $2.85 million from the same period last year.
收入比去年同期下降了285萬美元。
Past Earnings Performance
過去的收益表現
Last quarter the company beat on EPS by $0.01 which was followed by a 2.05% drop in the share price the next day.
上個季度,該公司的每股收益比每股收益高出0.01美元,隨後第二天股價下跌了2.05%。
Here's a look at Lineage Cell Therapeutics's past performance:
以下是Lineage Cell Therapeutics過去的表現:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | -0.04 | -0.03 | -0.04 | -0.03 |
EPS Actual | -0.03 | -0.04 | -0.04 | -0.04 |
Revenue Estimate | 2.57M | 3.90M | 3.68M | 7.32M |
Revenue Actual | 1.90M | 3.00M | 4.55M | 5.24M |
季度 | 2022 年第四季度 | 2022 年第三季度 | 2022 年第二季度 | 2022年第一季度 |
---|---|---|---|---|
每股收益估算 | -0.04 | -0.03 | -0.04 | -0.03 |
實際每股收益 | -0.03 | -0.04 | -0.04 | -0.04 |
收入估算 | 2.57M | 3.90 米 | 3.68M | 7.32M |
實際收入 | 1.90 米 | 3.00M | 4.55M | 5.24M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
要追蹤Lineage Cell Therapeutics發佈的所有財報,請在此處訪問他們的財報日曆。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動內容引擎生成,並由編輯審閱。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧